(trospium chloride + xanomeline tartrate)

all catalysts(0)

nothing on the calendar yet

News(10)

• Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
  Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
  biopharma_dive · 2d ago
• BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
  Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…
  biospace · 3d ago
• Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
  Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.
  fiercebiotech · 3d ago
• MapLight CEO on what investors missed in the biotech’s schizophrenia data
  Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."
  biopharma_dive · 4d ago
• MapLight dives despite positive data for schizophrenia drug
  Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
  biopharma_dive · 6d ago
• MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
  While MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb's Cobenfy is likely to hold its market share.
  biospace · 6d ago
• MapLight shares sink on mixed phase 2 schizophrenia readout
  MapLight Therapeutics’ stock plummeted more than 60% this morning after the neuro outfit dropped mixed results for a phase 2 trial of its experimental schizophrenia treatment.
  fiercebiotech · 6d ago
• 10 clinical trials to watch in the second half of 2026
  The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
  biopharma_dive · 1mo ago
• Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
  Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
  biopharma_dive · 3mo ago
• Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
  Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
  biopharma_dive · 3mo ago